Aytu Biopharma (AYTU) Research & Development (2014 - 2026)

Aytu Biopharma (AYTU) has reported Research & Development for 13 consecutive years, with $5.9 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Research & Development rose 14.15% year-over-year to $5.9 million in Q1 2026; TTM through Mar 2026 was $22.0 million, a 2.24% increase from a year earlier, with the FY2025 full-year figure at $20.9 million, down 5.33% from the prior year.
• Research & Development was $5.9 million for Q1 2026 at Aytu Biopharma, down from $6.0 million in the prior quarter.
• Over five years, Research & Development peaked at $12.8 million in Q1 2023 and troughed at $4.8 million in Q2 2025.
• A 5-year average of $7.1 million and a median of $5.9 million in 2026 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 31.42% in 2023 and slumped 58.2% in 2024, its largest moves.
• Over 5 years, Research & Development stood at $10.6 million in 2022, then tumbled by 50.59% to $5.2 million in 2023, then increased by 1.03% to $5.3 million in 2024, then advanced by 13.77% to $6.0 million in 2025, then retreated by 1.15% to $5.9 million in 2026.
• The last three Research & Development figures came in at $5.9 million (Q1 2026), $6.0 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.